Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older

ConclusionsThe benefit-risk profile for MenACYW-TT showed favorable seroresponse and seroprotection in individuals aged  ≥ 2 years and no difference in risk criteria between MenACYW-TT and MCV4s. MenACYW-TT may provide an alternative to the standard-of-care for meningococcal disease prevention in those aged ≥ 12 months.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research